CR9870A - Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist - Google Patents

Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist

Info

Publication number: CR9870A
Authority: CR; Costa Rica
Prior art keywords: prostaglandin; dihydrogen phosphate; phosphate salt; receiver antagonist; antagonist
Prior art date: 2005-10-13

Application number

CR9870A

Other languages

English (en)

Inventor

Beverly Langevin

Edwuard Orton

Daniel Sherer

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-13

Filing date

2008-04-07

Publication date

2008-06-18

2008-04-07 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2008-06-18 Publication of CR9870A publication Critical patent/CR9870A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CR9870A 2005-10-13 2008-04-07 Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist CR9870A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US72629005P	2005-10-13	2005-10-13

Publications (1)

Publication Number	Publication Date
CR9870A true CR9870A (es)	2008-06-18

Family

ID=37963090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9870A CR9870A (es)	2005-10-13	2008-04-07	Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist

Country Status (35)

Country	Link
US (1)	US7642249B2 (es)
EP (1)	EP1948620B1 (es)
JP (1)	JP2009511591A (es)
KR (1)	KR101365480B1 (es)
CN (1)	CN101287714B (es)
AR (1)	AR058085A1 (es)
AU (1)	AU2006304187B2 (es)
BR (1)	BRPI0617311A2 (es)
CA (1)	CA2625563C (es)
CR (1)	CR9870A (es)
DK (1)	DK1948620T3 (es)
DO (2)	DOP2006000220A (es)
EC (1)	ECSP088362A (es)
ES (1)	ES2409833T3 (es)
GT (1)	GT200600457A (es)
HN (1)	HN2008000603A (es)
HR (1)	HRP20130341T1 (es)
IL (1)	IL190673A (es)
MA (1)	MA30005B1 (es)
MY (1)	MY145648A (es)
NI (1)	NI200800116A (es)
NO (1)	NO20082072L (es)
NZ (1)	NZ567433A (es)
PE (1)	PE20070791A1 (es)
PL (1)	PL1948620T3 (es)
PT (1)	PT1948620E (es)
RS (1)	RS52799B (es)
RU (1)	RU2419614C2 (es)
SI (1)	SI1948620T1 (es)
TN (1)	TNSN08131A1 (es)
TW (1)	TW200728288A (es)
UA (1)	UA93062C2 (es)
UY (1)	UY29862A1 (es)
WO (1)	WO2007047378A2 (es)
ZA (1)	ZA200802586B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN2005000795A (es) *	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
AR060403A1 (es) *	2006-04-12	2008-06-11	Sanofi Aventis	Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
EA200802417A1 (ru) *	2006-06-09	2009-06-30	Икос Корпорейшн	Замещенные фенилуксусные кислоты как dp-2-антагонисты
EP2170837B1 (en) *	2007-06-29	2011-11-02	Sanofi	Process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl)-phenyl)-2-methylpropionic acid
WO2009099902A1 (en)	2008-02-01	2009-08-13	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2245022A4 (en) *	2008-02-25	2012-02-22	Panmira Pharmaceuticals Llc	ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en)	2008-10-01	2013-02-19	Panmira Pharmaceuticals, Llc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US20100112606A1 (en) *	2008-10-17	2010-05-06	Michael Armstrong	Measurement and analysis of leukotrienes
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
CA2768492A1 (en)	2009-07-31	2011-02-03	Panmira Pharmaceuticals, Llc	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2011017201A2 (en)	2009-08-05	2011-02-10	Amira Pharmaceuticals, Inc.	Dp2 antagonist and uses thereof
EP2590640A1 (en)	2010-07-08	2013-05-15	Ramot at Tel-Aviv University Ltd	Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
US8785467B2 (en) *	2010-09-30	2014-07-22	Merck Sharp & Dohme Corp.	Alkoxy pyrimidine PDE10 inhibitors
WO2014066568A1 (en)	2012-10-24	2014-05-01	Winthrop-University Hospital	Non-invasive biomarker to identify subjects at risk of preterm delivery
ES2991300T3 (es)	2015-02-13	2024-12-03	Inserm Institut Nat De La Sante Et De Larecherche Medicale	Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
KR102691467B1 (ko)	2015-06-04	2024-08-02	오리진 온콜로지 리미티드	Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
CA3075688A1 (en)	2017-09-13	2019-03-21	Progenity, Inc.	Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4711888A (en) *	1985-07-24	1987-12-08	Pfizer Inc.	Hydroxy and alkoxy pyrimidines
MXPA04005510A (es) *	2001-12-07	2006-02-24	Vertex Pharma	Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
AU2004255338A1 (en) *	2003-07-09	2005-01-20	F. Hoffmann-La Roche Ag	Thiophenylaminoimidazolines as prostaglandin I2 antagonists
HN2005000795A (es) *	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2

2006
- 2006-10-11 GT GT200600457A patent/GT200600457A/es unknown
- 2006-10-12 WO PCT/US2006/039901 patent/WO2007047378A2/en not_active Ceased
- 2006-10-12 BR BRPI0617311-0A patent/BRPI0617311A2/pt not_active IP Right Cessation
- 2006-10-12 PT PT68258367T patent/PT1948620E/pt unknown
- 2006-10-12 HR HRP20130341TT patent/HRP20130341T1/hr unknown
- 2006-10-12 NZ NZ567433A patent/NZ567433A/en not_active IP Right Cessation
- 2006-10-12 RU RU2008118491/04A patent/RU2419614C2/ru not_active IP Right Cessation
- 2006-10-12 PL PL06825836T patent/PL1948620T3/pl unknown
- 2006-10-12 MY MYPI20081085A patent/MY145648A/en unknown
- 2006-10-12 AU AU2006304187A patent/AU2006304187B2/en not_active Ceased
- 2006-10-12 DK DK06825836.7T patent/DK1948620T3/da active
- 2006-10-12 CN CN2006800378860A patent/CN101287714B/zh not_active Expired - Fee Related
- 2006-10-12 RS RS20130225A patent/RS52799B/sr unknown
- 2006-10-12 JP JP2008535672A patent/JP2009511591A/ja not_active Abandoned
- 2006-10-12 ES ES06825836T patent/ES2409833T3/es active Active
- 2006-10-12 EP EP06825836A patent/EP1948620B1/en active Active
- 2006-10-12 UA UAA200806196A patent/UA93062C2/ru unknown
- 2006-10-12 KR KR1020087008805A patent/KR101365480B1/ko not_active Expired - Fee Related
- 2006-10-12 PE PE2006001242A patent/PE20070791A1/es not_active Application Discontinuation
- 2006-10-12 SI SI200631572T patent/SI1948620T1/sl unknown
- 2006-10-12 CA CA2625563A patent/CA2625563C/en not_active Expired - Fee Related
- 2006-10-12 AR ARP060104475A patent/AR058085A1/es not_active Application Discontinuation
- 2006-10-13 TW TW095137635A patent/TW200728288A/zh unknown
- 2006-10-13 UY UY29862A patent/UY29862A1/es unknown
- 2006-10-13 DO DO2006000220A patent/DOP2006000220A/es unknown
- 2006-10-13 DO DO2006P000223A patent/DOP2006000223A/es unknown
2008
- 2008-03-19 TN TNP2008000131A patent/TNSN08131A1/en unknown
- 2008-03-20 ZA ZA200802586A patent/ZA200802586B/xx unknown
- 2008-04-07 CR CR9870A patent/CR9870A/es not_active Application Discontinuation
- 2008-04-07 IL IL190673A patent/IL190673A/en not_active IP Right Cessation
- 2008-04-10 EC EC2008008362A patent/ECSP088362A/es unknown
- 2008-04-11 US US12/101,282 patent/US7642249B2/en not_active Expired - Fee Related
- 2008-04-11 HN HN2008000603A patent/HN2008000603A/es unknown
- 2008-04-11 NI NI200800116A patent/NI200800116A/es unknown
- 2008-05-02 MA MA30890A patent/MA30005B1/fr unknown
- 2008-05-02 NO NO20082072A patent/NO20082072L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DOP2006000223A (es)	2007-05-15
RU2008118491A (ru)	2009-11-20
CA2625563A1 (en)	2007-04-26
NO20082072L (no)	2008-05-02
IL190673A0 (en)	2008-11-03
JP2009511591A (ja)	2009-03-19
IL190673A (en)	2011-12-29
ECSP088362A (es)	2008-05-30
NI200800116A (es)	2011-12-15
AU2006304187B2 (en)	2011-04-28
DOP2006000220A (es)	2007-05-15
NZ567433A (en)	2010-06-25
MA30005B1 (fr)	2008-12-01
EP1948620A2 (en)	2008-07-30
CN101287714A (zh)	2008-10-15
EP1948620B1 (en)	2013-03-20
PT1948620E (pt)	2013-05-06
UY29862A1 (es)	2007-05-31
UA93062C2 (ru)	2011-01-10
RU2419614C2 (ru)	2011-05-27
ZA200802586B (en)	2009-09-30
MY145648A (en)	2012-03-15
HN2008000603A (es)	2010-11-03
DK1948620T3 (da)	2013-06-24
AU2006304187A1 (en)	2007-04-26
HK1125133A1 (en)	2009-07-31
BRPI0617311A2 (pt)	2011-07-19
US7642249B2 (en)	2010-01-05
ES2409833T8 (es)	2013-09-26
WO2007047378A3 (en)	2007-08-02
SI1948620T1 (sl)	2013-05-31
HRP20130341T1 (en)	2013-05-31
TNSN08131A1 (en)	2009-07-14
ES2409833T3 (es)	2013-06-28
PE20070791A1 (es)	2007-08-16
KR101365480B1 (ko)	2014-02-21
RS52799B (sr)	2013-10-31
KR20080057275A (ko)	2008-06-24
PL1948620T3 (pl)	2013-08-30
GT200600457A (es)	2007-04-27
TW200728288A (en)	2007-08-01
CN101287714B (zh)	2011-04-06
WO2007047378A2 (en)	2007-04-26
CA2625563C (en)	2011-04-19
AR058085A1 (es)	2008-01-23
US20080194600A1 (en)	2008-08-14

Publication	Publication Date	Title
CR9870A (es)	2008-06-18	Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist
MA28876B1 (fr)	2007-09-03	Amides bicycliques comme inhibiteurs de kinases
ATE373003T1 (de)	2007-09-15	Phosphorsäuresalz eines dipeptidylpeptidase-iv- inhibitors
IL213070A (en)	2016-09-29	A method for determining the efficacy of PD-1 antagonist
BRPI1008829A2 (pt)	2016-03-15	forma cristalina de dihidrogenofosfato de (r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
ATE449762T1 (de)	2009-12-15	Kristalline formen einer biphenylverbindung
BRPI0811156A2 (pt)	2019-09-24	compostos antagonistas de rna para a modulação de her3
EP1926221A4 (en)	2011-12-28	Signal transmitter
ATE479682T1 (de)	2010-09-15	Kristalline form einer chinolin-carboxamid- verbindung
EP2023727A4 (en)	2009-12-09	PROSTAGLANDINTRANSPORTER INHIBITORS
BRPI0718444A2 (pt)	2013-11-19	Inibidores de receptor de adp de plaqueta
EP1935874A4 (en)	2010-10-13	S1P3 RECEPTOR ANTAGONIST
GB2438811B (en)	2008-10-15	Acoustic generator for measuring distances by echoes
ITPR20070098A1 (it)	2009-06-22	Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
EP1761562A4 (en)	2009-03-25	CONFORMATION SPECIFIC ANTIBODIES
PL1723157T3 (pl)	2008-04-30	Amorficzne postaci rizedronianu monosodowego
FR2915747B1 (fr)	2011-02-25	Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
DE602006003661D1 (de)	2008-12-24	Ampa-rezeptoren-verstärker
ZA200801431B (en)	2009-07-29	Solid salt forms of a pyrrole substituted 2-indolinone
FI20040702A0 (fi)	2004-05-21	Menetelmä fosfaattia sisältävän suspension valmistamiseksi
BRPI0621575A2 (pt)	2016-09-13	conjunto de peças de conexão para tubos cilindricos para brinquedos de montar em três dimensões
FR2938960B1 (fr)	2010-11-12	Procede de transmission d'une coordonnee geographique.
DE602005016615D1 (de)	2009-10-22	Kompensation der parasitären kopplung zwischen hf-ng
EE00727U1 (et)	2008-04-15	Meetod haruldase muldmetallihendi puhtuse mramiseks
EP1981976A4 (en)	2009-05-06	METHOD FOR CREATING TRANSCRIPTOSOME PROFILES

Legal Events

Date	Code	Title	Description
2013-08-29	FC	Refusal